Researchers at the University of Edinburgh have identified a unique blood-based “hormone fingerprint” that can detect endometriosis with over 95% accuracy. By measuring elevated levels of 11-ketotestosterone, a specific androgen, this discovery challenges the traditional estrogen-focused model of the disease and offers a potential path toward replacing invasive laparoscopic surgery with a simple diagnostic blood test.
How the Hormone Fingerprint Works
Endometriosis has long been categorized by medical science as a condition driven exclusively by estrogen and progesterone. However, a study published in the European Journal of Endocrinology reports that researchers shifted their focus toward androgens, specifically 11-oxygenated androgens produced by the adrenal glands. By comparing blood samples from 159 women with confirmed endometriosis against 57 women without the condition, the team identified significantly higher levels of 11-ketotestosterone in those affected.
The current diagnostic standard for endometriosis relies on laparoscopic surgery, which involves physically locating and biopsying tissue patches, a process that can lead to a diagnostic delay averaging nine years in the UK.
Why This Discovery Challenges Medical Assumptions
The reliance on an estrogen-only model has historically limited the scope of treatment and research for endometriosis. According to the Edinburgh team, the discovery of 11-ketotestosterone as a biomarker suggests that the adrenal-driven androgen pathway plays a more active role in the disease than previously recognized. This pivot in understanding could lead to the development of targeted therapeutics that move beyond conventional estrogen-blocking drugs.
What Happens Next for Diagnostic Development
Edinburgh Innovations, the commercialization service of the University of Edinburgh, is now actively seeking industry partners to scale this diagnostic technology. If validated in larger clinical trials, the blood test could reduce the diagnostic timeline from years to months. This transition would allow patients to access targeted treatments much earlier, potentially preventing the progression of inflammation and scar tissue associated with the disease.
Comparison: Current Diagnostic Pipeline vs. Proposed Blood Test
| Feature | Laparoscopic Surgery | Proposed Blood Test |
|---|---|---|
| Invasiveness | Highly invasive | Non-invasive |
| Diagnostic Delay | Average of 9 years | Months |
Frequently Asked Questions
How is endometriosis currently diagnosed?
Currently, the standard for diagnosis is laparoscopic surgery, which involves an invasive procedure to locate and biopsy tissue patches.
What makes this new blood test different?
Unlike current methods, this potential test is non-invasive and targets 11-ketotestosterone, a specific hormone fingerprint that identified over 95% of patients in the initial study cohort.
When will this test be available for patients?
The technology is currently in the commercialization phase. Edinburgh Innovations is seeking industry partners to scale the test, meaning it must undergo further validation in larger trials before clinical rollout.
Are you interested in the latest advancements in women’s health? Subscribe to our newsletter for updates on this diagnostic research and other medical breakthroughs.